BPI West 2027

BPI West 2027 takes place on 16–18 March 2027 at San Diego Convention Center, San Diego. It is organised by Informa Connect, and B2DB lists 92 speakers and 143 sessions announced so far.

BioProcess International US West (BPI West) 2027 is a bioprocessing conference and exhibition taking place on March 16-18, 2027 at the San Diego Convention Center in San Diego, California. It covers the path from early-stage process development to commercial manufacturing, including cell line development, upstream and downstream processing, cell and gene therapy manufacturing and CMC, with four pre-conference workshops. It is aimed at bioprocessing scientists, CMC, MSAT, regulatory and manufacturing leaders.

Key facts

Keynote speakers

• Richard Braatz, Ph.D. Edwin R. Gilliland Professor, Faculty Research Officer, Massachusetts Institute of Technology
• Jack Prior Head of Process Monitoring & Data Science/AI Strategy, Sanofi

Speakers (92)

Compiled from the published agenda; speakers can claim and verify their own entry.

• Richard Braatz, Ph.D. Edwin R. Gilliland Professor, Faculty Research Officer, Massachusetts Institute of Technology
• Jack Prior Head of Process Monitoring & Data Science/AI Strategy, Sanofi
• Mukunda Krishna Associate Director, External Manufacturing, Tech Ops and Supply Chain, Arcturus Therapeutics
• Alois Jungbauer Professor, Dept. of Biotechnology, BOKU University (BOKU)
• Maroun Beyrouthy, Ph.D. Senior Advisor, Eli Lilly and Company
• Mark Duerkop Chief Executive Officer, Novasign
• Amit Mathur, Ph.D. Principal Scientist, Sanofi
• Christoph Herwig, Ph.D. Former Professor of Biochemical Engineering, TU Wien. Serial entrepreneur, CEO Lisalis and Fermify, Lisalis
• Mahlon Schaffer Senior Scientist, Process Characterization and Technology, Regeneron
• Megan Cormace Associate Manager, Process Sciences, Regeneron
• Prasad Pathange, Ph.D. Director, CMC Process Development & Commercialization, Bayer U.S.
• Aishy Murali Process Development Engineer II, Downstream, Astellas Gene Therapies
• Ali Behboudi, Ph.D. Senior Scientist, Downstream Process Development, Pfizer
• Andres Soohoo Engineer II, Process Development, Astellas Gene Therapies
• Andrew L. Zydney, Ph.D. Bayard D. Kunkle Chair and Professor of Chemical Engineering, The Pennsylvania State University
• Anthony Chikere Director, Vector Process Development, Sangamo Therapeutics, Inc.
• Apurva Godbole, Ph.D. Senior Scientist, Analytical R&D, Merck & Co., Inc.
• Ashna Dhingra Senior Scientist, AstraZeneca
• Brooke Tam, Ph.D. USP Modeling Expert, Sanofi
• Callum Chapman Executive Director, Product Quality, Gilead
• Cassidy Sheehan Process Characterization and Technology Engineer, Regeneron
• Chad Varner, Ph.D. Associate Director, Sanofi
• David Garcia Munzer Director Scientific Office DSD, Novartis
• Deepti Tyagi MSAT, Amgen
• Dethardt Müeller, Ph.D. Chief Technology Officer, CMC, Abalos Therapeutics GmbH
• Divina Anunciado, Ph.D. Principal Scientist, Pfizer
• Eashwar Rajaraman Principal Scientist I, Novartis
• Elisabeth Krug, Ph.D. Executive Director, Eli Lilly & Company
• Ellie McGhee Process Characterization and Technology Engineer, Regeneron
• Geneva Alok, Ph.D. Principal Scientist, Process Development, Amgen
• Gregory Keil Scientific Director, Global Upstream and Cell Line Development, Bristol-Myers Squibb
• Irina Ramos, Ph.D Senior Director, Johnson & Johnson Innovative Medicine
• Isaura (Alex) Villalba Senior Research Associate, Tr1X, Inc.
• Jan Schoning Vice President, Drug Product Biologicals, Boehringer Ingelheim
• Jara Lin, Ph.D. Executive Director, BeOne Medicines
• Jason Dowd, Ph.D., MBA Global Lead Cell Therapy Platform, Bayer
• Jeffrey Baker Senior Fellow, NIIMBL; Strategic Advisor, CBI-MIT, ex-Deputy Director, Office of Biotechnology Product, CDER, FDAs
• Jinlin Jiang, Ph.D. Director, AstraZeneca
• Joseph Shultz Vice President, Technical Development, Ottimo Pharma
• Juan Zou Downstream Process Development Scientist II, Alexion, AstraZeneca Rare Disease
• Julie Beaudet Senior Staff Scientist, CMC Regulatory Sciences, Regeneron
• Kabir Dhingra, Ph.D. Senior Scientist, Merck
• Kaiyue Wu Senior Scientist, Sanofi
• Kyle McElearney Director, Amgen
• Lee Peters, Ph.D. Process Development Senior Scientist, Amgen
• Lev Starikov, Ph.D. Associate Director, Process Development, BlueRock Therapeutics
• Lianchun Fan, Ph D. Senior Research Fellow, Senior Director of Early Biologics Excellence Center, Abbvie Bioresearch Center
• Lina Chakrabarti, Ph.D. Principal Scientist, BioPharmaceutical Development, Astrazeneca
• Mahendra Rao, Ph.D. Chief Scientific Officer, Vita Therapeutics
• Matthew Radle Senior Scientist, Analytical Sciences – Physicochemical Development, AstraZeneca
• Meghana Teli Senior Research Scientist, Incyte Corporation
• Michael Coolbaugh Head of Advanced Manufacturing Implementation, Sanofi
• Nancy Guillen, Ph.D. Associate Director, Johnson and Johnson Innovative Medicines
• Nikita Tatwadhia Scientist, AstraZeneca
• Nuno Carinhas, Ph.D. Fellow, Upstream Process Development, Novartis
• Paniz Hadjian Engineer I, Upstream Process Development, Astellas Pharma
• Paul Rousseau Sr. Engineer II, Cell Line Development, Biogen
• Poorvaja Ganesan Associate Scientist 3, Alexion
• Sanjay Ranjit, Ph.D. Senior Scientist, Takeda Pharmaceuticals Company Limited
• Santosh Paidi Technical Development Principal Scientist, Genentech
• Saurabh Sen, Ph.D. Director, Cell Line Development, Global CMC, Sanofi
• Scott H. Altern, Ph.D. Senior Scientist II, AbbVie
• Shankar Swaminathan, Ph.D. Team Lead, Drug Product Development, CMC-Tech Ops, Astellas Institute for Regenerative Medicine
• Shyam Panjwani Senior Principal CMC Data Scientist, Bayer
• Sisi Zhang, MSc. Principal Scientist, Analytical and Biological Mass Spectrometry, Regeneron
• Sobhana Sripada Senior Engineer, Process Development and Clinical Supply, Alexion Pharmaceuticals
• Stefano Menegatti Professor, Chemical and Biomolecular Engineering, NC State University, North Carolina State University
• Thomas Jacobsen, Ph.D. GMP Scientist/Lead,, Duke Human Vaccine Institute
• Thomas Seewoester, Ph.D. Vice President, Site Operations, Amgen
• Tianxin Zhang, Ph.D. Senior Scientist, AstraZeneca
• Tim Boung Wook Lee, Ph.D. Senior Principal Scientist, Johnson and Johnson
• Timo Frensing Director, Bayer
• Verzhiniya Aho Senior Scientist, Pfizer
• Vida Rahmatnejad, Ph.D. Upstream Development Scientist, Alexion
• Wanzhu Zhao Scientist I, Astellas Pharma Inc.
• Xiaolu Chen, M.D. Associate Scientist IV, Alexion AstraZeneca Rare Disease
• Xiaoyan Tang, MD Principle Scientist, Merck & Co., Inc.
• Yashas Rajendra Ph.D. Director & Principal Scientist, Denali Therapeutics
• Zhengqi Zhang Senior Scientist, Merck
• Zhenqiu Huang, Ph.D. Senior Scientist, Merck & Co., Inc.
• Zorica Dragic, Ph.D. Unit Head Cell Line Screening and Development, Novartis
• Aaron Coleman Scientist, Denali Therapeutics
• Chadakarn Sirasittichoke Principal Data Scientist, Bristol Myers Squibb
• Dong-Qiang Lin Professor, Zhejiang University
• Huize Yan Senior Scientist, Genentech
• Mark Tie Principal Scientist, Biogen
• MarkVic Naniong Head of CMC, Kiragen Bio
• Mukesh Mayani Senior Director, Ultragenyx
• Rajeev Boregowda Associate Director, Bioassay & Molecular Analytical Development, Genomic Medicine CMC, Sanofi
• Satish Kallappagoudar Associate Principal Scientist, Merck
• Thomas FitzSimons Senior Scientist, AbbVie
• Xiaoxiang Zhu Group Lead, Senior Scientist, Amgen

Most represented companies

• Sanofi — 8 speakers
• Amgen — 6 speakers
• AstraZeneca — 6 speakers
• Regeneron — 6 speakers
• Novartis — 4 speakers
• Bayer — 3 speakers
• Merck — 3 speakers
• Merck & Co., Inc. — 3 speakers
• Pfizer — 3 speakers
• AbbVie — 2 speakers

Agenda (143 sessions)

Day 1 — Tuesday 16 March 2027

• Chairperson's Opening Remarks 08:55–09:00 · Workshop 3: AI, Data, and Digital Transformation in Bioprocessing: From Data Management to Autonomous Processing
• Chairperson's Opening Remarks 08:55–09:00 · Workshop 2: Process Intensification in Practice: From Intensified to End-to-End Bioprocessing
• Chairperson's Opening Remarks 08:55–09:00 · Workshop 1: Tech Transfer Done Better: How to Minimize the Knowledge Gap
• Chairperson's Opening Remarks 08:55–09:00 · Workshop 4: From Raw Data to Regulatory-Ready Process Models: A Hands-On Workshop in Biopharmaceutical Process Modeling
• Scientific Case Study 09:00–09:30 · Workshop 2: Process Intensification in Practice: From Intensified to End-to-End Bioprocessing — Nikita Tatwadhia
• From Raw Data to Regulatory-Ready Process Models: A Hands-On Workshop in Biopharmaceutical Process Modeling 09:00–10:30 · Workshop 4: From Raw Data to Regulatory-Ready Process Models: A Hands-On Workshop in Biopharmaceutical Process Modeling — Mark Duerkop
• Workshop 3: AI, Data, and Digital Transformation in Bioprocessing: From Data Management to Autonomous Processing 09:00–09:30 · Workshop 3: AI, Data, and Digital Transformation in Bioprocessing: From Data Management to Autonomous Processing
• Workshop 1: Tech Transfer Done Better: How to Minimize the Knowledge Gap 09:00–10:30 · Workshop 1: Tech Transfer Done Better: How to Minimize the Knowledge Gap
• Challenges and Emerging Approaches in Upstream Process Development: Productivity, Product Quality, and Modeling 09:30–10:00 · Workshop 2: Process Intensification in Practice: From Intensified to End-to-End Bioprocessing — Gregory Keil
• Scientific Case Study 10:00–10:30 · Workshop 2: Process Intensification in Practice: From Intensified to End-to-End Bioprocessing — Michael Coolbaugh
• Workshop 1: Tech Transfer Done Better: How to Minimize the Knowledge Gap 11:00–12:00 · Workshop 1: Tech Transfer Done Better: How to Minimize the Knowledge Gap
• From Raw Data to Regulatory-Ready Process Models: A Hands-On Workshop in Biopharmaceutical Process Modeling 11:00–12:30 · Workshop 4: From Raw Data to Regulatory-Ready Process Models: A Hands-On Workshop in Biopharmaceutical Process Modeling — Mark Duerkop
• Smart Continuous Manufacturing of Biotherapeutics: Modeling, Analytics, and Control 11:00–11:30 · Workshop 2: Process Intensification in Practice: From Intensified to End-to-End Bioprocessing — Richard Braatz, Ph.D.
• Workshop 3: AI, Data, and Digital Transformation in Bioprocessing: From Data Management to Autonomous Processing 11:00–12:00 · Workshop 3: AI, Data, and Digital Transformation in Bioprocessing: From Data Management to Autonomous Processing
• Orchestrating Continuous Purification Processes – Pilot Plant Case Studies 11:30–12:00 · Workshop 2: Process Intensification in Practice: From Intensified to End-to-End Bioprocessing — Chad Varner, Ph.D.
• Panel Discussion: Intensified Today, End-to-End Tomorrow? What's Really Standing in the Way? 12:00–12:30 · Workshop 2: Process Intensification in Practice: From Intensified to End-to-End Bioprocessing
• Panel Discussion - How do we make the AI advancements more accessible to the industry? 12:00–12:30 · Workshop 3: AI, Data, and Digital Transformation in Bioprocessing: From Data Management to Autonomous Processing
• Panel Discussion - Intangible, Non-Technical Aspects of Transfers 12:00–12:30 · Workshop 1: Tech Transfer Done Better: How to Minimize the Knowledge Gap
• Lunch 'n' Learn Presentations 13:00–13:45 · Networking Break
• Chairperson's Opening Remark 13:55–14:00 · BPI WEST Main Conference Opening Plenary
• Speed Without Shortcuts: How AI is Transforming CMC and Validation at Amgen 14:00–14:45 · BPI WEST Main Conference Opening Plenary — Thomas Seewoester, Ph.D.
• Keynote Plenary Session 14:45–15:30 · BPI WEST Main Conference Opening Plenary

Day 2 — Wednesday 17 March 2027

• Chairperson's Opening Remarks 08:55–09:00 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing
• Chairperson's Opening Remarks 08:55–09:00 · Cell Line Development & Engineering
• Chairperson's Opening Remarks 08:55–09:00 · Downstream Processing
• Chairperson's Opening Remarks 08:55–09:00 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
• Chairperson's Opening Remarks 08:55–09:00 · Cell Culture & Upstream Processing
• Keynote Address: Intensification of Cell and Gene Therapy Manufacturing: Modeling, Design, and Control 09:00–09:30 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Richard Braatz, Ph.D.
• Fueling CHO Performance: Strategic Media and Feed Optimization Across Scales 09:00–09:30 · Cell Culture & Upstream Processing — Meghana Teli
• Fast to Clinic, Fast to Launch: Record Breaking Speed to the Patient 09:00–09:30 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Joseph Shultz
• Engineering the Future of Biotherapeutics: From Cell Lines to Patient Impact 09:00–09:30 · Cell Line Development & Engineering — Zorica Dragic, Ph.D.
• Integrating Automation and Mechanistic Modeling to Enable Rapid Purification Development of Challenging Molecules 09:00–09:30 · Downstream Processing — Scott H. Altern, Ph.D.
• Scientific Case Study 09:30–10:00 · Cell Culture & Upstream Processing — Kyle McElearney
• Keynote Address: CMC Challenges and Opportunities in an Evolving CGT Landscape 09:30–10:00 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
• Scientific Case Study 09:30–10:00 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Shyam Panjwani
• Advancing Process Development with Online HPLC-Enabled PAT 09:30–10:00 · Downstream Processing — Divina Anunciado, Ph.D.
• Accelerating Recombinant Protein Manufacturing: Process Intensification and Next-Generation Transient Expression Strategies 09:30–10:00 · Cell Line Development & Engineering — Thomas Jacobsen, Ph.D.
• Product Development of a Phase III (and Beyond) Parkinson’s Allogeneic Cell Therapy using Process and Analytic Platforms 10:00–10:30 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Jason Dowd, Ph.D., MBA
• Single Cycle Biologics Development at FIH 10:00–10:30 · Cell Line Development & Engineering — Lianchun Fan, Ph D.
• Overcoming Downstream Purification Bottlenecks using Advanced Analytics and In-silico Approaches 10:00–10:30 · Downstream Processing — Kabir Dhingra, Ph.D.
• Optimizing Fed-Batch CHO Cell Culture Through Media and Feed Strategy to Improve Productivity and Product Quality 10:00–10:30 · Cell Culture & Upstream Processing — Xiaolu Chen, M.D.
• Scientific Case Study 10:00–10:30 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Deepti Tyagi
• Not Every Opportunity is a Priority: Strategic Process Development at BlueRock 11:15–11:45 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Lev Starikov, Ph.D.
• Untagged Proteins and Removal of Impurities Via Chromatography Steps 11:15–11:45 · Downstream Processing
• Development and Application of a Phase-Dependent Dynamic Design of Experiments Framework for Fed-Batch Cell Culture Processes 11:15–11:45 · Cell Culture & Upstream Processing — Tim Boung Wook Lee, Ph.D.
• Enhanced Seed Train Design Overcomes Challenges in Non-Perfusion Intensified Fed-Batch (NPIFB) Platform Development 11:15–11:45 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Jara Lin, Ph.D.
• Mastering Complex Antibodies: Intelligent Design for High Titers and Superior Product Quality 11:15–11:45 · Cell Line Development & Engineering — Saurabh Sen, Ph.D.
• Accelerating Upstream Turnaround: Leveraging Intracellular Stress Signatures for Rapid Process Interventions 11:45–12:15 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing
• A High-Throughput Approach to Virus Retentive Filtration Process Development and Characterization 11:45–12:15 · Downstream Processing
• Accelerating AAV Process Development Through SEC-MALS 11:45–12:15 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Andres Soohoo
• Unlocking Productivity in an Upstream Continuous Process by Combining Media Concentrates and Multi-Phase Feeding 11:45–12:15 · Cell Culture & Upstream Processing — Nuno Carinhas, Ph.D.
• Scientific Case Study 11:45–12:15 · Cell Line Development & Engineering — Geneva Alok, Ph.D.
• Scientific Track Presentation 12:15–12:45 · Downstream Processing
• Scientific Track Presentation 12:15–12:45 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
• Scientific Track Presentation 12:15–12:45 · Cell Line Development & Engineering
• Scientific Track Presentation 12:15–12:45 · Cell Culture & Upstream Processing
• Scientific Track Presentation 12:15–12:45 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing
• Understanding Drivers of Harvest Performance: From Process Specific Treatments to Cross Process Analysis 14:00–14:30 · Downstream Processing — Vida Rahmatnejad, Ph.D.
• Integrating Automation and Real-Time PAT for Enhanced Cell Culture Process Control 14:00–14:30 · Cell Culture & Upstream Processing — Poorvaja Ganesan
• Innovating Within Control: A CMC Strategy for Regulatory Readiness for AAV based therapies 14:00–14:30 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Anthony Chikere
• Building Manufacturing Agility: Platform Processes, Digital Tech Transfer, and Closed Seed Train Innovations for CHO Antibody Production 14:00–14:30 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Timo Frensing
• Accelerating Cell Line Development: Saving Time and Increasing Capacity 14:00–14:30 · Cell Line Development & Engineering — Lina Chakrabarti, Ph.D.
• Accelerating AAV Downstream Process Development Through Automated, High-Throughput Chromatography Screening 14:30–15:00 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Aishy Murali
• Rapid Screening to Compare Process Conditions and Identify Low-Risk Conditions for PS80 Degradation in Downstream Process Development 14:30–15:00 · Downstream Processing — Juan Zou
• Engineering Automated Sampling, Purification, and Analytical Methods to Facilitate Online Product Quality Monitoring to Support Bioprocess Development 14:30–15:00 · Cell Culture & Upstream Processing — Matthew Radle
• Scientific Case Study 14:30–15:00 · Cell Line Development & Engineering — Santosh Paidi
• Commercial Readiness Early On – What Does this Mean for Analytical Development? 14:30–15:00 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Elisabeth Krug, Ph.D.
• Scientific Track Presentation 15:00–15:30 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing
• Scientific Track Presentation 15:00–15:30 · Cell Culture & Upstream Processing
• Scientific Track Presentation 15:00–15:30 · Cell Line Development & Engineering
• Scientific Track Presentation 15:00–15:30 · Downstream Processing
• Scientific Track Presentation 15:00–15:30 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
• Novel Strategies for Formulating High Concentration Biopharmaceuticals 16:15–16:45 · Downstream Processing — Andrew L. Zydney, Ph.D.
• Cell Culture Digital Twins for Improving Process Scale-Up 16:15–16:45 · Cell Culture & Upstream Processing — Brooke Tam, Ph.D.
• From Process Development to Regulatory Filing: AI-Assisted Workflows Across Development, Scale-Up, Manufacturing to Autonomous Control 16:15–16:45 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Mark Duerkop
• Innovating Within Control: A CMC Strategy for Regulatory Readiness for AAV based therapies 16:15–16:45 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Mahendra Rao, Ph.D.
• Rational Vector Design and Screening Strategies for Bispecific Cell Line Development via Random Integration 16:15–16:45 · Cell Line Development & Engineering — Paul Rousseau
• Mechanistic Modeling for Decision-Based Bioreactor Scale-Up 16:45–17:15 · Cell Culture & Upstream Processing — Ashna Dhingra
• Panel Discussion: What Is Really Slowing CMC Down in 2027? 16:45–17:15 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Christoph Herwig, Ph.D.
• Integrated Countercurrent Single-Pass TFF: Continuous Concentration and Buffer Exchange in One Pass 16:45–17:15 · Downstream Processing — Ali Behboudi, Ph.D.
• A Robust Cell Line Platform to Eliminate Xylosylation Without Compromising Cell Culture Performance, Productivity, and Product Quality 16:45–17:15 · Cell Line Development & Engineering — Xiaoyan Tang, MD
• Scientific Case Study 16:45–17:15 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Shankar Swaminathan, Ph.D.
• Panel Discussion: What Will Actually Change Advanced Therapy Manufacturing in the Next Five Years? 17:15–17:45 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
• Panel Discussion: How Far Can Platform Cell Line Development Really Go? 17:15–17:45 · Cell Line Development & Engineering
• Panel Discussion: The New Economics of Downstream - Throughput, COGS, and Capacity Strategy 17:15–17:45 · Downstream Processing — Alois Jungbauer
• Live Digital Twins and Agentic AI Enable Titer Prediction and Early Error Detection: Towards Self-Driving Biomanufacturing 17:15–17:45 · Cell Culture & Upstream Processing — Tianxin Zhang, Ph.D.

Day 3 — Thursday 18 March 2027

• Chairperson's Opening Remarks 08:55–09:00 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing
• Chairperson's Opening Remarks 08:55–09:00 · Cell Line Development & Engineering
• Chairperson's Opening Remarks 08:55–09:00 · Cell Culture & Upstream Processing
• Chairperson's Opening Remarks 08:55–09:00 · Downstream Processing
• Chairperson's Opening Remarks 08:55–09:00 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
• Accelerating mRNA Vaccine Development with a Cell-Free DNA Template Platform 09:00–09:30 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Kaiyue Wu
• Keynote Address: Are We Here Yet? A Digital Maturity Model for Enabling Process Monitoring and Artificial Intelligence in Biologics Manufacturing 09:00–09:30 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Jack Prior
• Implementing a Lower-Cost Resin in a Licensed Process: A CMC Case Study 09:00–09:30 · Cell Culture & Upstream Processing / Downstream Processing — Prasad Pathange, Ph.D.
• End-to-End Automation of Cell Line Development: From Workflow Integration to Streamlined Execution 09:00–09:30 · Cell Line Development & Engineering — Lee Peters, Ph.D.
• Scientific Case Study 09:30–10:00 · Cell Culture & Upstream Processing — Alois Jungbauer
• Scientific Case Study 09:30–10:00 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
• Accelerating Cell Line Development with Digital and Sequencing-Enabled Characterization 09:30–10:00 · Cell Line Development & Engineering — Zhenqiu Huang, Ph.D.
• Scientific Case Study 09:30–10:00 · Downstream Processing — Alois Jungbauer
• Need of Holistic Control Strategies 09:30–10:00 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Christoph Herwig, Ph.D.
• Panel Discussion: Supply Chain, Data Governance, and the End-to-End Value Chain for Advanced Therapies 10:00–10:30 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Mukunda Krishna
• Scientific Case Study 10:00–10:30 · Cell Line Development & Engineering — Yashas Rajendra Ph.D.
• Panel Discussion: Internal vs. External Execution - How to Move Faster With CDMOs and Partner Networks 10:00–10:30 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing
• Shared Panel Discussion: How can Bioprocess Engineering Reduce Manufacturing Costs? 10:00–10:30 · Cell Culture & Upstream Processing / Downstream Processing — Alois Jungbauer, Prasad Pathange, Ph.D., Irina Ramos, Ph.D
• Shared Session: AMBR Based Harvest PAR Models 11:15–11:45 · Cell Line Development & Engineering — Mahlon Schaffer, Megan Cormace
• Considerations for Proper Potency Method Development for Conjugated Therapeutics 11:15–11:45 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Maroun Beyrouthy, Ph.D.
• High Throughput Purification Using Automated Resin Slurry for Resin Screening 11:15–11:45 · Downstream Processing — Cassidy Sheehan, Ellie McGhee
• PAT Solutions for CQAs 11:15–11:45 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Jan Schoning
• From Seed Train to Harvest: Scaling Down Process Characterization with the AMBR250 11:15–11:45 · Cell Culture & Upstream Processing — Mahlon Schaffer, Megan Cormace
• Biotechnology Readiness Levels(BRL) 11:45–12:15 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Jeffrey Baker
• Integrated Mass Spectrometry and Molecular Modeling Reveal Off-Target Tyrosine Conjugation in a Sulfonylpyrimidine-Based ADC 11:45–12:15 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Zhengqi Zhang
• Scientific Case Study 11:45–12:15 · Downstream Processing — Eashwar Rajaraman
• Shared Session: AAV upstream Development Through an Automated, High-Throughput Ambr250 Scale- Down Platform 11:45–12:15 · Cell Line Development & Engineering / Cell Culture & Upstream Processing — Paniz Hadjian
• Scientific Track Presentation 12:15–12:45 · Cell Line Development & Engineering
• Scientific Track Presentation 12:15–12:45 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing
• Scientific Track Presentation 12:15–12:45 · Cell Culture & Upstream Processing
• Scientific Track Presentation 12:15–12:45 · Downstream Processing
• Scientific Track Presentation 12:15–12:45 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
• Using Modeling and Simulation, Together with Prior Knowledge, to Accelerate Late-Stage Process Development 14:00–14:30 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — David Garcia Munzer
• Accelerating RPE Electroporation Optimization Through Design of Experiments 14:00–14:30 · Cell Line Development & Engineering — Wanzhu Zhao
• Root-Cause Investigation of Protein A Ligand Leaching on Aged MabSelect SuRe Resin 14:00–14:30 · Downstream Processing — Sisi Zhang, MSc.
• Scientific Case Study 14:00–14:30 · Cell Culture & Upstream Processing
• Beyond Ex Vivo CAR-T: Designing Lentiviral Vector Manufacturing for In Vivo Cell Therapy 14:00–14:30 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Jinlin Jiang, Ph.D.
• Integration of Experimental Execution, Statistics and Multivariate Data Analysis to Optimize Process Performance and Product Quality in the Production of Multispecific Antibody Therapies in CHO Cells 14:30–15:00 · Cell Culture & Upstream Processing — Nancy Guillen, Ph.D.
• Scientific Case Study 14:30–15:00 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Julie Beaudet
• Intelligent AAV Cell Line Development: AI-Powered Automation and Rapid Screening 14:30–15:00 · Cell Line Development & Engineering — Amit Mathur, Ph.D.
• High-throughput Characterization of Empty/Full AAV Separation for Tech Transfer Support 14:30–15:00 · Downstream Processing — Sobhana Sripada
• From Bench to Bioprocess: Overcoming Challenges in the Evolving Landscape of Plasmid Manufacturing for Cell and Gene Therapy 14:30–15:00 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Alois Jungbauer
• Scientific Track Presentation 15:00–15:30 · Cell Culture & Upstream Processing
• Scientific Track Presentation 15:00–15:30 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
• Scientific Track Presentation 15:00–15:30 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing
• Scientific Track Presentation 15:00–15:30 · Cell Line Development & Engineering
• Scientific Track Presentation 15:00–15:30 · Downstream Processing
• Dielectric Spectroscopy for Monitoring a Bioprocess 16:15–16:45 · Cell Culture & Upstream Processing
• A Case Study: Purification of Bi-Specific Antibodies and Fc-fusion Proteins 16:15–16:45 · Downstream Processing — Stefano Menegatti
• Scientific Case Study 16:15–16:45 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Callum Chapman
• Mastering Four-Chain Balance: Vector Engineering Strategies for High-Performance Bispecific Antibody Expression in CHO Cells 16:15–16:45 · Cell Line Development & Engineering — Sanjay Ranjit, Ph.D.
• Overcoming Manufacturing Challenges through Donor Screening Platform to Limit Lot failures for Allogeneic Therapies 16:15–16:45 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Isaura (Alex) Villalba
• Panel Discussion: How Far Can Platform Development Really Go? A Cross-Track View on Standardization 16:45–17:15 · Cell Culture & Upstream Processing
• Panel Discussion: What Will Actually Change Cell Line Development in the Next Five Years? 16:45–17:15 · Cell Line Development & Engineering — Amit Mathur, Ph.D.
• From Innovation to the Clinic: Navigating the Challenges of Platform Manufacturing for Arenavirus-Based Cancer Immunotherapies 16:45–17:15 · Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production — Dethardt Müeller, Ph.D.
• Split, Switch, and Stitch: Generating Multispecific Antibodies Using Column Based Redox Reactions 16:45–17:15 · Downstream Processing — Verzhiniya Aho
• From Cell Culture to Fill–Finish: Integrated PAT in Biologics Production 17:15–17:45 · Accelerating Speed from Early Stage Development Through Commercial Manufacturing — Apurva Godbole, Ph.D.

Organisers, sponsors and partners

Organiser (1)

Informa Connect

Sponsors (38)

Accuflow Systems · Thermo Fisher · Benchling · Hamilton Company · Avenue Biosciences · Crystal Technologies and Industries · Boston Institute of Biotechnology · BASF · Getinge · Avid Bioservices · Chemglass Life Sciences · Sartorius Stedim Biotech GmbH · Membrane Solutions · ACROBiosystems · KBI Biopharma · Gyros Protein Technologies · HIPRA Biotech Services · Croda Pharma · Syngene · Single Use Support · Beckman Coulter Life Sciences · Cytiva · Lisure · Nova Biomedical · Brenntag · Boston BioProducts · Culture Biosciences · Cyth Systems · Bruker Cellular Analysis · Foxx Life Sciences · Astoriom · PendoTECH · Repligen · Optimal Biotech Group · Asimov · Biolife Solutions · Bionova Scientific · ChemoMetec

Media Partners (4)

Biopharma Asia · BioProcess Insider · Kind Congress · Life Sciences Review

Association Partners (6)

OUTBio San Diego · Latios in Bio · BCLA - Biotech Connection Los Angeles · BioPhorum · The Society of Professional Pharmaceutical Consultants · California Life Sciences (CLS)

Exhibitors (36)

Accuflow Systems · Benchling · Hamilton Company · Avenue Biosciences · Crystal Technologies and Industries · Boston Institute of Biotechnology · BASF · Getinge · Avid Bioservices · Chemglass Life Sciences · Sartorius Stedim Biotech GmbH · Membrane Solutions · ACROBiosystems · KBI Biopharma · Gyros Protein Technologies · HIPRA Biotech Services · Croda Pharma · Syngene · Single Use Support · Beckman Coulter Life Sciences · Cytiva · Lisure · Nova Biomedical · Brenntag · Boston BioProducts · Culture Biosciences · Cyth Systems · Foxx Life Sciences · Astoriom · PendoTECH · Repligen · Optimal Biotech Group · Asimov · Biolife Solutions · Bionova Scientific · ChemoMetec

Supporting Partners (3)

Life Science Cares - San Diego · French Bio Beach · Taylor and Francis

Source: the published agenda. See how B2DB compiles its records.